A Phase 3 study of etavopivat in sickle cell disease

Recruiting Phase 3 NCT06612268

Study Description

Evaluating the effectiveness of etavopivat in reducing sickle cell pain crises and improving overall health in people with sickle cell disease

Study Details

Registry ID:
NCT06612268
Conditions:
Sickle Cell Disease
Phase:
Phase 3
Target Enrollment:
408 participants
Start Date:
Healthy Volunteers:
No

Study Locations (229 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.org.

View full study details and check eligibility →